19Dec
As its COVID-19 Vaccine Nears Finalization, AstraZeneca Announces Deal to Buy Alexion for $39 Billion
AstraZeneca, the British-Swedish multinational pharmaceutical company currently collaborating with the University of Oxford on a COVID-19 vaccine, will purchase Alexion Pharmaceuticals for $39 billion. The transaction, which awaits approval by shareholders and regulators, is the largest purchase by a health care company this year and is expected to close in the third quarter of 2021. Alexion was founded in 1992 and is headquartered in Boston but has a global presence. It is known for its...
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
Imagine if Mark Zuckerberg hatched the idea for Facebook, yet all he did was talk about the site ins...
Read More >
The most frequently asked question at all-hands meetings for a securities offering is “What financi...
Read More >
Digital transformation will fundamentally change how you operate your business and deliver value to ...
Read More >
Reaction to recent trial losses; focus of enforcement will remain on mergers between competitors - ...
Read More >
Tech M&A has remained strong in 2019, registering only a moderate decline against a much sharper fal...
Read More >
One of the ways to operationalize compliance and to drive it into the DNA of an organization is thro...
Read More >